The PD-1 inhibitor Daboshu® Phase III clinical study reached the primary endpoint of overall survival

On August 16, Innovent announced that it has jointly developed an innovative drug PD-1 inhibitor Daboshu® combined with chemotherapy (oxaliplatin + capecitabine) for the first-line treatment of unresectable locally advanced and recurrent unresectable, jointly developed with Eli Lilly.

Gastric cancer is one of the most common malignant tumors in the world.

Currently in China, the first-line treatment for advanced or metastatic gastric cancer is mainly platinum-containing two- or three-drug chemotherapy.

It is reported that more than 20 clinical studies have been conducted so far to evaluate the anti-tumor effect of Sintilimab on various solid tumors and hematological tumors

The Phase III clinical study (ORIENT-16) is a comparison of Sintilimab or placebo, combined with chemotherapy (oxaliplatin + capecitabine) for the first-line treatment of unresectable locally advanced, recurrent or metastatic A randomized, double-blind, multicenter, phase III study on the effectiveness and safety of adenocarcinoma at the gastroesophageal junction (ClinicalTrials.

Based on the interim analysis data conducted by the Independent Data Monitoring Committee (iDMC), for both the intention-to-treat (ITT) population and the PD-L1 positive population, the combination of sintilimab and chemotherapy significantly prolonged the overall survival of patients At the end of the period (OS), the pre-set superiority standard is reached, and the safety characteristics are consistent with the previously reported clinical research results of Sintilimab, and there is no new safety signal